In the latest session Abbott shares fell 1.43%, undercutting the broader healthcare index which gained 0.8% on the day. Volume was elevated at 8.2 million shares, nearly 30% above its ten‐day average, suggesting heightened investor interest. Analysts cited concerns over near‐term diagnostic revenue headwinds and currency fluctuations in key European markets as primary drivers of the pullback.

Abbott raised its quarterly dividend by 6.8% to $0.63 per share, marking the 52nd consecutive annual increase. This brings the annualized payout to $2.52 per share, representing a yield of approximately 1.9%. In 2024 the company generated $6.35 billion in free cash flow against $3.84 billion in total dividend payments, yielding a free cash flow payout ratio of 60.4%. During Q3 2025, free cash flow of $2.29 billion comfortably covered dividend distributions of $1.03 billion, implying a quarterly payout ratio of 45%.

By Q3 2025 total debt had declined 15% from year‐end 2024 to $12.9 billion, driving the debt‐to‐equity ratio down to 0.25x. Net debt stood at $5.4 billion versus trailing EBITDA of $11.75 billion, keeping net leverage below 0.5x and interest coverage north of 68x. Shareholder equity expanded to $51.0 billion with retained earnings of $49.1 billion. On the revenue side, medical devices led growth with a 12.5% increase—anchored by quarterly FreeStyle Libre sales of $2.0 billion—while established pharmaceuticals rose 7%, nutrition climbed 4%, and diagnostics began rebounding as pandemic testing comparisons ease, supporting management’s outlook for mid‐single‐digit revenue growth and double‐digit EPS expansion through 2026.